Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 9/20 | 0.45 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.43 |
| ▸ | MARS1 | P56192 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935125 | 0.90 | MGLL (0.47) | MALT1MARS1MGLLCHRNA7 | |
| SCHEMBL4925391 | 0.90 | KDM1A (0.44) | KDM1A | |
| SCHEMBL4927907 | 0.85 | KDM1A (0.46) | KDM1AMALT1MGLL | |
| SCHEMBL4931848 | 0.82 | CHRNA7 (0.46) | MALT1MARS1MGLLCHRNA7 | |
| SCHEMBL4933051 | 0.82 | MGLL (0.51) | MALT1MARS1MGLLNTRK1 | |
| SCHEMBL4931030 | 0.82 | MGLL (0.45) | MALT1MARS1MGLLNTRK1SPR | |
| SCHEMBL4932922 | 0.81 | MALT1 (0.52) | KDM1AMALT1MARS1MGLLCHRNA7 | |
| SCHEMBL14564105 | 0.80 | NTRK1 (0.49) | MALT1MARS1MGLLNTRK1 | |
| SCHEMBL14261654 | 0.79 | KDM1A (0.43) | KDM1AMGLL | |
| SCHEMBL4931595 | 0.79 | VNN1 (0.42) | KDM1AMALT1MARS1MGLLCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | KDM1A 559/4885MALT1 2474/4885MARS1 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.